Shore Capital Reaffirms Buy Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN - Get Free Report)'s stock had its "buy" rating restated by Shore Capital in a note issued to investors on Tuesday, MarketBeat.com reports.

A number of other research analysts have also weighed in on AZN. Berenberg Bank reissued a "buy" rating and set a GBX 140 ($1.86) price target on shares of AstraZeneca in a research report on Wednesday, March 26th. JPMorgan Chase & Co. reissued an "overweight" rating on shares of AstraZeneca in a research report on Wednesday, February 19th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, AstraZeneca has an average rating of "Moderate Buy" and an average target price of GBX 6,303.50 ($83.67).

AstraZeneca Stock Up 1.0 %

Shares of AZN stock traded up GBX 108.82 ($1.44) during trading hours on Tuesday, reaching £107.17 ($142.25). The company had a trading volume of 2,186,306 shares, compared to its average volume of 17,705,582. The business has a fifty day simple moving average of £110.46 and a 200-day simple moving average of £109.75. AstraZeneca has a 12 month low of GBX 9,573.51 ($127.07) and a 12 month high of £133.88 ($177.70). The company has a market cap of £206.19 billion, a price-to-earnings ratio of 29.38, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.